» Articles » PMID: 18798074

Can the Lack of HSP90alpha Protein in Brain Normal Tissue and Cell Lines, Rationalise It As a Possible Therapeutic Target for Gliomas?

Overview
Journal Cancer Invest
Specialty Oncology
Date 2008 Sep 18
PMID 18798074
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Despite studies suggesting a role for HSP90alpha in tumorigenesis, there are no reports as to its expression in normal human brain tissue. In this study, the expression of HSP90alpha was evaluated in both cell lines (3 gliomas and 2 controls) and brain tissue specimens of 10 patients (8 gliomas and 2 normal brain tissues). No HSP90alpha protein was detected in either normal cell lines or normal brain tissue. However, 8/8 glioma tissues and 3/3 glioma cell lines did express HSP90alpha. These findings provide a rationale for targeting HSP90alpha protein as a therapeutic candidate for glioma.

Citing Articles

Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma.

Tseng H, Banerjee S, Qian B, Lai M, Wu T, Hsu T Eur J Med Chem. 2023; 256:115459.

PMID: 37172473 PMC: 10247544. DOI: 10.1016/j.ejmech.2023.115459.


Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid Arthritis.

Shervington L, Darekar A, Shaikh M, Mathews R, Shervington A Biomark Insights. 2018; 13:1177271918801005.

PMID: 30262983 PMC: 6153528. DOI: 10.1177/1177271918801005.


A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.

Mehta A, Shervington L, Munje C, Shervington A Cancers (Basel). 2013; 3(4):4228-44.

PMID: 24213135 PMC: 3763420. DOI: 10.3390/cancers3044228.


Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?.

Mehta A, Shervington A, Howl J, Jones S, Shervington L FEBS Open Bio. 2013; 3:271-8.

PMID: 23905009 PMC: 3722647. DOI: 10.1016/j.fob.2013.06.002.


The development and characterization of protein-based stationary phases for studying drug-protein and protein-protein interactions.

Sanghvi M, Moaddel R, Wainer I J Chromatogr A. 2011; 1218(49):8791-8.

PMID: 21704318 PMC: 3183392. DOI: 10.1016/j.chroma.2011.05.067.